9-ING-41 + Carboplatin for Salivary Gland Cancer

Recruiting in Palo Alto (17 mi)

+1 other location

Glenn J. Hanna, MD - Dana-Farber Cancer ...

Overseen byGlenn J. Hanna, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Glenn J. Hanna

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new drug called 9-ING-41 for patients with advanced salivary gland cancers that don't respond to usual treatments. The new drug aims to slow down the cancer by blocking a specific function that helps cancer cells grow.

Eligibility Criteria

Adults with advanced salivary gland cancer, including adenoid cystic carcinoma, who have not responded to previous treatments or whose disease has returned. They must be in relatively good health with proper organ and bone marrow function, able to provide tissue samples, and willing to use effective contraception.

Inclusion Criteria

At least one RECIST v1.1 measurable non-CNS based lesion

I have recovered from the side effects of my last cancer treatment.

My scans show new or worsening cancer spots within the last year.

+8 more

Exclusion Criteria

I have another cancer that is getting worse or needs treatment.

Pregnant or lactating women

I have cancer that has spread to my brain or surrounding membranes.

+4 more

Participant Groups

The trial is testing the effectiveness of a new drug called 9-ING-41 (a GSK-3β inhibitor) when given through IV alongside Carboplatin chemotherapy. The goal is to see if this combination can help treat advanced salivary gland cancers more effectively.

1Treatment groups

Experimental Treatment

Group I: 9-ING-41 + carboplatinExperimental Treatment2 Interventions

Participants will be divided into 2 cohorts: Salivary Gland Cancer with adenoid cystic carcinoma (ACC) and Salivary Gland Cancer without adenoid cystic carcinoma (ACC) and receive: * 9-ING-41 2x every 21 day study cycle on Day 1 and Day 4 up to 1 year with option to continue beyond if participant is showing benefit * Carboplatin 1x every 21 day study cycle on Day 1 up to 1 year